Navigation Links
New amyloid-reducing compound could be a preventive measure against Alzheimer's
Date:6/2/2014

Scientists at NYU Langone Medical Center have identified a compound, called 2-PMAP, in animal studies that reduced by more than half levels of amyloid proteins in the brain associated with Alzheimer's disease. The researchers hope that someday a treatment based on the molecule could be used to ward off the neurodegenerative disease since it may be safe enough to be taken daily over many years.

"What we want in an Alzheimer's preventive is a drug that modestly lowers amyloid beta and is also safe for long term use," says Martin J. Sadowski, MD, PhD, associate professor of neurology, psychiatry, and biochemistry and molecular pharmacology, who led the research to be published online June 3 in the journal Annals of Neurology. "Statin drugs that lower cholesterol appear to have those properties and have made a big impact in preventing coronary artery disease. That's essentially what many of us envision for the future of Alzheimer's medicine."

The 2-PMAP molecule that Dr. Sadowski's team identified is non-toxic in mice, gets easily into the brain, and lowers the production of amyloid beta and associated amyloid deposits.

The prime target for Alzheimer's prevention is amyloid beta. Decades before dementia begins, this small protein accumulates in clumps in the brain. Modestly lowering the production of amyloid beta in late middle age, and thus removing some of the burden from the brain's natural clearance mechanisms, is believed to be a good prevention strategy. Researchers two years ago reported that something like this happens naturally in about 0.5 percent of Icelanders, due to a mutation they carry that approximately halves amyloid beta production throughout life. These fortunate people show a slower cognitive decline in old age, live longer, and almost never get Alzheimer's.

Prevention of Alzheimer's dementia is now considered more feasible than stopping it after it has begun, when brain damage is already severe. Every prospective Alzheimer's drug in clinical trials has failed even to slow the disease process at that late stage. "The key is to prevent the disease process from going that far," Dr. Sadowski says.

Dr. Sadowski and colleagues screened a library of compounds and found that 2-PMAP reduced the production of amyloid beta's mother protein, known as amyloid precursor protein (APP). The APP protein normally is cut by enzymes in a way that leaves amyloid beta as one of the fragments. Dr. Sadowski's team found that 2-PMAP, even at low, non-toxic concentrations, significantly reduced APP production in test cells, lowering amyloid beta levels by 50 percent or more.

The scientists subsequently found that 2-PMAP had essentially the same impact on APP and amyloid beta in the brains of living mice. The mice were engineered to have the same genetic mutations found in Alzheimer's patients with a hereditary form of the disease, causing overproduction of APP and Alzheimer's-like amyloid deposits. A five-day treatment with 2-PMAP lowered brain levels of APP and, even more so, levels of amyloid beta. Four months of treatment sharply reduced the amyloid deposits and prevented the cognitive deficits that are normally seen in these transgenic mice as they get older.

Dr. Sadowski and his laboratory are now working to make chemical modifications to the compound to improve its effectiveness. But 2-PMAP already seems to have advantages over other amyloid-lowering compounds, he says. One is that it can cross efficiently from the bloodstream to the brain, and thus doesn't require complex modifications that might compromise its effects on APP.

The compound also appears to have a highly selective effect on APP production, by interfering with the translation of APP's gene transcript into the APP protein itself. The best known candidates for Alzheimer's preventives lower amyloid by inhibiting the secretase enzymes that cleave amyloid beta from APP, tending to cause unwanted side-effects via their off target interference with the processing of other client proteins cleaved by these enzymes. A clinical trial of one secretase inhibitor was halted in 2010 after it was found to worsen dementia and cause a higher incidence of skin cancer.

Alzheimer's disease, the most common form of dementia, currently afflicts more than five million Americans, according to the Alzheimer's Association. Unless preventive drugs or treatments are developed, the prevalence of Alzheimer's is expected to triple by 2050.


'/>"/>

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Red wine, fruit compound could help block fat cell formation
2. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
3. Biosynthetic grape-derived compound prevents progression of Alzheimers disease in mice
4. Could Compound in Artificial Sweeteners Worsen Crohns Disease?
5. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
6. Breast-Milk Compound May Shield Babies From HIV
7. Red wine compound could help seniors walk away from mobility problems
8. Green tea compound shows promise for tackling cancer
9. Compounds activate key cancer enzyme to interfere with tumor formation
10. Second Compounding Pharmacy Shut Down in Massachusetts
11. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
(Date:4/28/2017)... New York, New York (PRWEB) , ... April ... ... of high-quality anti-aging skincare and advanced nutraceutical supplements, through its Nova ... fast-absorbing cream provides the hydrating benefits of a moisturizer with the power of ...
(Date:4/27/2017)... PHILADELPHIA and DENVER (PRWEB) , ... April 27, ... ... Jewish Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an ... Institute is enabled by the continuing support of the Jane and Leonard Korman ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins ... the Year for her extraordinary compassion and lifelong dedication to serve others. Since ... caregivers for the prestigious award each year – identifying a CAREGiver who has ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 The Mobile ... to showcase a healthy CAGR during the forecast period ... type in the global digital mobile X-Ray devices market, which ... Mn in 2017, expanding at a CAGR of 7% over ... absolute $ opportunity of more than US$ 100 Mn in ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
Breaking Medicine Technology: